Proactive Investors
14 Jul 2026, 06:54 UTC · 2h ago
CelLBxHealth reaffirms revenue guidance
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
14 Jul 2026, 06:54 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CelLBxHealth PLC expects to deliver revenues of at least £2.1 million for 2026, a 50% increase over 2025. — Strong projected revenue growth is a primary driver for valuation in small-cap biotech firms.
+0.60Solvonis Therapeutics PLC reports new data supporting its lead alcohol use disorder programme prior to a planned Phase 2b trial. — Positive pre-trial data increases the probability of clinical success and opens a significant addressable US market.
+0.40CelLBxHealth PLC is currently searching for a new chief executive. — Leadership transitions can create short-term uncertainty and execution risk, though the chairman claims no operational impact.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Positive new data supports its lead alcohol use disorder programme ahead of a Phase 2b trial.
The company is on track for a 50% revenue increase in 2026 despite searching for a new CEO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
23h ago
